|
|
Article: Axcan Announces Positive Phase II Efficacy and Safety Results for ITAX in the Treatment of Functional Dyspepsia.
- Article from:
- PR Newswire
- Article date:
- May 20, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
-Dr. Gerald Holtmann presents results at Digestive Disease Week-
Axcan Pharma Inc. ("Axcan" or the "Company") recently announced positive efficacy and safety results of a Phase II study for ITAX (Itopride hydrochloride) concluding that ITAX was significantly better than placebo for symptom-control in patients with functional dyspepsia after 4 and 8 weeks. No cardiac toxicity was observed in the study group. Dr. Gerald Holtmann, Professor at the University of Essen, Germany, presented the results at Digestive Disease (DDW) week on May 19, 2004.
"The opportunity of increasing the awareness of ITAX's potential at the world's largest international ...